What's New
Advancing Hope: AFTD Staff Attend NORD Breakthrough Summit in Washington, DC
Shana Dodge, PhD, AFTD’s Director of Research Engagement and Meghan Buzby, MBA, AFTD’s Director of Advocacy and Volunteer Engagement attended the National Organization for Rare Disorders (NORD) Breakthrough Summit, held…
GemVax & KAEL Announces Results from Phase 2a Clinical Trial for PSP
South Korean biopharmaceutical company GemVax & Kael announced in late October the results from its phase 2a clinical trial evaluating a drug for PSP. While the drug failed to show…
Dear HelpLine: Navigating Travel During the Holidays
Dear HelpLine, I am thinking of traveling to see family this year for the holidays, but this would be the first time taking my wife since she was diagnosed with…
A Conversation with Alector’s Vice President of Clinical Development
Earlier this year, the biopharmaceutical company Alector announced that the U.S. Food and Drug Administration (FDA) had granted a “breakthrough therapy designation” to latozinemab, the company’s investigational drug designed to…
Vesper Bio Announces Successful Completion of Phase 1 Study for Potentially Disease-Modifying Treatment for FTD-GRN
Biotechnology company Vesper Bio announced in early September that the phase 1 clinical trial for its potentially disease-modifying treatment for FTD-GRN has successfully concluded. The company noted data from the…
November 24, 2024: In-Person Meet & Greet in Manchester, NH
Join and learn from others who understand the FTD journey at this in-person AFTD Meet & Greet event, hosted by AFTD Ambassador Shirley Gordon and Kevin Rhodes, co-chair of the…
AFTD Webinar: Diagnosing Primary Progressive Aphasia
With primary progressive aphasia (PPA), problems with language and communication typically deteriorate gradually over time. Initial symptoms are sometimes attributed to anxiety or stress until the ongoing symptoms become disruptive…
Advancing Hope: AFTD hosts 2024 FTD Research Roundtable Meeting
The FTD Research Roundtable is an annual program designed to accelerate FTD drug development by convening various scientific stakeholders to identify common challenges and advance solutions for FTD clinical trials.…
AC Immune and Life Molecular Imaging Announce FDA Fast Track Designation for Tau PET Tracer
Swiss biopharmaceutical company AC Immune announced in late August that its partner, German biopharmaceutical company Life Molecular Imaging (LMI), received a Fast Track Designation from the US Food and Drug…